WEBINAR: Gunderson Dettmer Hosts Tackling the Lifecycle of Affinivax: From Inception to Exit

Gunderson Dettmer hosted the Tackling the Lifecycle of Affinivax: From Inception to Exit webinar to discuss Affinivax’s trajectory from an early-stage vaccine start-up to its $3.3 billion acquisition by GSK. Gunderson Dettmer partner Tim Ehrlich, Affinivax CEO Steve Brugger, Affinivax Chief Business Officer Stuart Chaffee, and J.P. Morgan Global Chairman Philip Ross led the webinar and shared insights about Affinivax’s acquisition.

Discussion topics from this event include

• Initial fundraising
• Strategic partnering strategy
• Scaling the business with growth equity/IPO
• Reacquiring a program from a partner
• Managing a clinical-stage asset
• Staying independent vs. selling
• Selling the business

To watch the webinar video, click here.

Companies
Affinivax
GSK